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Background: Bleeding has emerged as a predictor of early and late mortality after percutaneous coronary interventions. However, the prevalence 
and predictors of long-term bleeding events in patients (pts) on prolonged dual antiplatelet therapy after drug-eluting stent (DES) implantation has 
been poorly explored.
Methods: We studied 1358 consecutive pts undergoing DES implantation and discharged on dual antiplatelet therapy with aspirin and clopidogrel 
for 1 year. Pts were followed-up for 12 months and the prevalence and predictors of in-hospital and long-term TIMI major and minor bleeding events 
were evaluated. The impact of bleeding events on all cause death, major adverse cardiac events (MACE), probable, possible and definite stent 
thrombosis, and premature discontinuation of antiplatelet therapy were also assessed.
Results: The incidence of in-hospital major and minor bleeding was 1.2% and 3.7%, respectively. The incidence of cumulative long-term major and 
minor bleeding was 4.2% and 8.2%, respectively. At multivariable analysis, cumulative long-term major bleeding was predicted only by haemoglobin 
at admission (OR=0.44 [0.35-0.55], p<0.001), whereas haemoglobin at discharge (OR=0.62 [0.54-0.72], p<0.001), beta-blockers (OR=0.53 
[0.30-0.95], p=0.03), and oral anticoagulants at discharge (OR=5.59 [2.28-13.70], p<0.001) predicted cumulative long term minor bleeding. The 
incidence of one-year mortality (23.6% vs 3.8%, p<0.001), MACE (47.3% vs 12.5%, p<0.001), and stent thrombosis (12.7% vs 3.1%, p=0.002) was 
significantly higher in pts who experienced a major bleeding event. Pts who had a major bleeding event were more likely to prematurely discontinue 
antiplatelet therapy (11.5% vs 63.6%, p<0.001). Minor bleeding was associated with increased rates of MACE (25.2% vs 13%, p=0.001) and 
premature antiplatelet therapy discontinuation (44.9% vs 10.9%, p<0.001).
Conclusions: In DES treated pts on dual antiplatelet therapy, long-term major bleeding is predicted by lower levels of haemoglobin at admission. 
Pts experiencing any bleeding event are more likely to discontinue prematurely antiplatelet therapy and have a higher risk of MACE.
